The selective VEGFR1‐3 inhibitor axitinib (AG‐013736) shows antitumor activity in human neuroblastoma xenografts
Jochen Rößler(University Medical Center Freiburg), Birgit Geoerger(Hôpital de la Timone)
Cited by 61
Related Papers
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors
|Neuro-Oncology|2010|159
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
|PLoS ONE|2015|57
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts
|International Journal of Cancer|2008|56
Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors
|International Journal of Oncology|2016|44